Rosen Law Firm Sues Inovio Pharmaceuticals
Analysis based on 50 articles · First reported Feb 10, 2026 · Last updated Mar 05, 2026
The market is negatively impacted by the news of a class action lawsuit against Inovio Pharmaceuticals, as it raises concerns about the company's integrity and future financial performance. Investors who purchased Inovio Pharmaceuticals securities during the Class Period may suffer damages.
Rosen Law Firm has announced a class action lawsuit against Inovio Pharmaceuticals, Inc. on behalf of investors who purchased securities between October 10, 2023, and December 26, 2025. The lawsuit alleges that Inovio Pharmaceuticals made false and misleading statements regarding deficiencies in the manufacturing of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application to the United States===Food and Drug Administration by the second half of 2024. Furthermore, the lawsuit claims Inovio Pharmaceuticals had insufficient information to justify INO-3107's eligibility for FDA accelerated approval or priority review, thus overstating its regulatory and commercial prospects. Investors are encouraged to join the class action by April 7, 2026, to potentially recover damages.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard